Unit dose of an aryl sulfonamide that is effective for treating eye disease and averting potential vision loss

Patent metadata

Field	Value
Publication number	US-10478433-B2
Application number	US-201816007880-A
Country	US
Kind code	B2
Filing date	Jun 13, 2018
Priority date	Jan 28, 2014
Publication date	Nov 19, 2019
Grant date	Nov 19, 2019

Abstract

Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

First claim

The invention claimed is:

1. A unit dose of a pharmaceutical composition formulated for treating of an ophthalmic disease or disorder in an eye of a subject;
wherein the unit dose contains a formulation of an effective amount of the compound (R)—N-(4-(4-(3-(2-(4-chlorophenyl)-1-isopropyl-5-methyl-4-(methylsulfonyl)-1H-pyrrol-3-yl)-5-fluorophenyl)piperazin-1-yl)phenyl)-4-((4-(4-hydroxypiperidin-1-yl)-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide (BM-1197) or a salt thereof, compounded in a defined volume;
wherein the formulation, the amount of the compound, and the defined volume configure the unit dose to be safe and effective for treating the ophthalmic disease or disorder when administered intraocularly into the eye of the subject.

2. The unit dose according to claim 1 , wherein the ophthalmic disease or disorder is a back-of-the-eye disease.

3. The unit dose according to claim 2 , wherein the ophthalmic disease or disorder is age-related macular degeneration (AMD).

4. The unit dose according to claim 1 , wherein the ophthalmic disease or disorder is glaucoma.

5. The unit dose according to claim 1 , wherein the ophthalmic disease or disorder is not a cancer.

6. The unit dose according to claim 1 , wherein the formulation of the composition, the amount of the compound, and the defined volume configure the unit dose to be safe and effective for preventing or delaying vision loss.

7. The unit dose according to claim 1 , wherein the unit dose is formulated for intravitreal injection.

8. The unit dose according to claim 1 , wherein the formulation of the composition, the amount of the compound, and the defined volume configure the unit dose to be safe and effective when administered to the eye by intravitreal injection.

9. The unit dose according to claim 1 , wherein the formulation of the composition, the amount of the compound, and the defined volume configure the unit dose to be effective in removing from the eye p16-positive senescent cells that are causing one or more symptoms of the ophthalmic disease or disorder.

10. The unit dose according to claim 1 , wherein the amount of the compound configures the unit dose to be effective in treating the ophthalmic condition when administered as a single dose.

11. The unit dose according to claim 1 , wherein the amount of the compound configures the unit dose to be effective in at least partially relieving symptoms of the ophthalmic conditions for at least one month following administration.

12. The unit dose according to claim 1 , wherein the amount of the compound configures the unit dose to be effective in delaying progression of the ophthalmic conditions for at least one month following administration.

13. The unit dose according to claim 1 , packaged in a kit containing a plurality of such doses.

14. A product that comprises a unit dose according to claim 1 and a package insert that describes the use and attendant benefits of the unit dose in treating a back-of-the-eye disease.

15. The product of claim 14 , wherein the back-of-the-eye disease is age-related macular degeneration (AMD).

16. A product that comprises a unit dose according to claim 1 in an appliance or device that is configured for dispensing the unit dose intraocularly into the eye of the subject.

17. A unit dose containing an effective amount of a compound having the following formula, or a pharmaceutically effective salt thereof;

wherein the unit dose is formulated as a pharmaceutical composition in an excipient in a volume suitable for intraocular administration into an eye of a subject in need thereof;
wherein the amount of the compound in the unit dose renders the unit dose effective for treating an ophthalmic disease or disorder in the eye that is not a cancer.

18. A unit dose of a pharmaceutical composition in a formulation for intravitreal administration into an eye of a subject in need thereof;
wherein the pharmaceutical composition contains the compound (R)—N-(4-(4-(3-(2-(4-chlorophenyl)-1-isopropyl-5-methyl-4-(methylsulfonyl)-1H-pyrrol-3-yl)-5-fluorophenyl)piperazin-1-yl)phenyl)-4-((4-(4-hydroxypiperidin-1-yl)-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide, or a pharmaceutically acceptable salt thereof,
wherein the formulation of the composition, an amount of the compound, and a volume of the unit dose configure the unit dose to be safe and effective for removing p16-positive senescent cells that are not cancer cells from the eye of the subject.

19. The unit dose according to claim 18 , wherein the p16-positive senescent cells are causing or mediating one or more symptoms of an ophthalmic disease or disorder in the eye.

20. The unit dose according to claim 18 , wherein the formulation of the composition, the amount of the compound, and the volume of the unit dose configure the unit dose to be effective in reducing the number of the senescent cells in the eye of the subject for at least two weeks following a single administration of the unit dose.

Assignees

• Unity Biotechnology Inc
• Buck Inst Res Aging
• Mayo Found Medical Education & Res

Inventors

• Laberge Remi-Martin
• Campisi Judith
• Demaria Marco
• David Nathaniel
• Baker Darren J
• Kirkland James L
• Tchkonia Tamar
• Zhu Yi
• Van Deursen Jan M A
• Vasserot Alain Philippe
• Childs Bennett G

Classifications

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/496 Primary

  Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title